PHLPP2

PH domain leucine-rich repeat-containing protein phosphatase 2 · Q6ZVD8 · PHLPP2 on Sugi Atlas →

17,160 patent compounds predicted against PHLPP2, 11,754 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL741689	0.51	8/20
SCHEMBL497248	0.65	6/20
SCHEMBL135508	0.58	5/20
SCHEMBL428681	0.58	5/20
Olsalazine (SCHEMBL29767)	0.54	5/20
Ipsalazide (SCHEMBL596652)	0.53	5/20
SCHEMBL596802	0.52	5/20
SCHEMBL596803	0.52	5/20
Olsalazine (SCHEMBL414570)	0.47	5/20
Olsalazine (SCHEMBL25118)	0.72	4/20
Olsalazine (SCHEMBL25119)	0.72	4/20
Olsalazine (SCHEMBL29769)	0.70	4/20
SCHEMBL133646	0.62	4/20
SCHEMBL133647	0.62	4/20
Resorcin Brown (SCHEMBL110506)	0.47	4/20
Resorcin Brown (SCHEMBL110507)	0.47	4/20
Resorcin Brown (SCHEMBL185544)	0.46	4/20
Resorcin Brown (SCHEMBL185546)	0.46	4/20
SCHEMBL1347625	0.42	4/20
SCHEMBL92089	0.37	4/20

Clinical trials — most relevant to PHLPP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome	nan	ACTIVE_NOT_RECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients	nan	UNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Activation of Hippo Pathway in Nasal Polyps	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Autophagy Bladder Cancer	nan	UNKNOWN
Biomarkers of CASH	nan	ACTIVE_NOT_RECRUITING
Platelet Hyperreactivity Project	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PHLPP2 binder may also engage these)

Protein	Name	Similarity
Q8BXA7	—	1.000	Q8BXA7 →
Q3SZD4	—	0.958	Q3SZD4 →
Q6EDY6	—	0.958	Q6EDY6 →
Q9BV38	—	0.957	Q9BV38 →
A0JMZ3	—	0.955	A0JMZ3 →
Q91009	—	0.955	Q91009 →
Q6NYU2	—	0.954	Q6NYU2 →
Q5TYQ1	—	0.953	Q5TYQ1 →
Q5ZLN0	—	0.953	Q5ZLN0 →
Q9DAK3	—	0.953	Q9DAK3 →
O94844	—	0.952	O94844 →
Q1LY10	—	0.952	Q1LY10 →
Q5VZK9	—	0.952	Q5VZK9 →
Q6UXM1	—	0.951	Q6UXM1 →
Q6P1C6	—	0.951	Q6P1C6 →
Q91W86	—	0.951	Q91W86 →
Q1LVW0	—	0.951	Q1LVW0 →
Q96CX6	—	0.950	Q96CX6 →
Q80WC9	—	0.949	Q80WC9 →
Q4VBE8	—	0.949	Q4VBE8 →
P0C7A6	—	0.949	P0C7A6 →
E7FAM5	—	0.948	E7FAM5 →
P48553	—	0.948	P48553 →
Q7TT36	—	0.947	Q7TT36 →
Q3UGP9	—	0.947	Q3UGP9 →
P11716	—	0.947	P11716 →
MALT1	Mucosa-associated lymphoid tissue lymphoma translocation protein 1	0.947	landscape →
Q52KR2	—	0.947	Q52KR2 →
RYR1	Ryanodine receptor 1	0.947	landscape →
O88954	—	0.947	O88954 →